<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391569</url>
  </required_header>
  <id_info>
    <org_study_id>1042-SE-3003</org_study_id>
    <nct_id>NCT04391569</nct_id>
  </id_info>
  <brief_title>RAndomized Therapy In Status Epilepticus</brief_title>
  <acronym>RAISE</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness and safety of an investigational product, IV
      ganaxolone, to treat subjects with status epilepticus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and
      safety of IV ganaxolone in status epilepticus. Investigational product will be added to
      standard of care before IV anesthetic during the treatment of SE. Subjects will be screened
      for inclusion/exclusion criteria prior to receiving investigational product by continuous IV
      infusion. Subjects will be followed for approximately 4 weeks.

      Subjects who are known to be at risk for SE may be consented or assented prior to an SE
      event.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SE Cessation</measure>
    <time_frame>30 minutes</time_frame>
    <description>Proportion of participants with status epilepticus cessation within 30 minutes of IP initiation without medications for the acute treatment of status epilepticus. SE cessation is determined by clinical and EEG findings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression to IV anesthesia</measure>
    <time_frame>36 hours</time_frame>
    <description>Proportion of participants with no progression to IV anesthesia for 36 hours following IP initiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to IV anesthesia</measure>
    <time_frame>72 hours</time_frame>
    <description>No progression to IV anesthesia for 72 hours following IP initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SE Cessation</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to SE cessation following IP initiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Status Epilepticus</condition>
  <condition>Convulsive Status EPILEPTICUS</condition>
  <condition>Non-Convulsive Status Epilepticus</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV ganaxolone active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>Double-blind study that will randomize subjects to ganaxolone or placebo in 1:1 ratio.</description>
    <arm_group_label>IV ganaxolone active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double-blind study that will randomize subjects to ganaxolone or placebo in 1:1 ratio.</description>
    <arm_group_label>IV Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical and/or electrographic seizures

        Exclusion Criteria:

          -  life expectancy of less than 24 hours

          -  anoxic brain injury for an uncontrolled metabolic condition as primary cause of SE

          -  treatment of current SE episode with IV anesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Gasior, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maciej Gasior, MD, PhD</last_name>
    <phone>484-639-4875</phone>
    <email>mgasior@marinuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Van Heusen, M Ed</last_name>
    <phone>484-802-2470</phone>
    <email>hvanheusen@marinuspharma.com</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seizure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

